Nanjing Synnocare Pharmaceutical Technology Co. Ltd. has described poly(ADP-ribose) glycohydrolase (PARG) inhibitors reported to be useful for the treatment of cancer.

Galapagos NV has divulged probable global transcription activator SNF2L2 (SMARCA2; BAF190B; SNF2-α) inhibitors reported to be useful for the treatment of cancer.

Astellas Engineered Small Molecules US Inc. has identified poly(ADP-ribose) polymerase (PARP) inhibitors, particularly PARP-1 (ARTD1), reported to be useful for the treatment of neuronal injury.

Kangbaida (Sichuan) Biotechnology Co. Ltd. has synthesized pyrrolidine derivatives acting as Toll-like receptor 7 (TLR7) and/or (TLR8) antagonists reported to be useful for the treatment of autoimmune disease.

Rednvia Co. Ltd. has disclosed alkaline phosphatase tissue-nonspecific isozyme (TNAP) inhibitors reported to be useful for the treatment of ectopic calcification.

Gan & Lee Pharmaceuticals Co. Ltd. has described protein cereblon (CRBN) inhibitors and proteolysis targeting chimera (PROTAC) compounds reported to be useful for the treatment of cancer.

Treeline Biosciences Inc. has divulged proteolysis targeting chimeras (PROTACs) comprising cereblon (CRBN) ligands coupled to a Bcl-2-like protein 1 (Bcl-xl; Bcl-X; BCL2L1) targeting moiety via a linker acting as Bcl-xl degradation inducers reported to be useful for the treatment of cancer.

Researchers at Chongqing Pharmaceutical Research Institute Co. Ltd. and Yaopharma Co. Ltd. have identified glucagon-like peptide 1 receptor (GLP-1R) agonists reported to be useful for the treatment of obesity, type 2 diabetes and nonalcoholic or metabolic dysfunction-associated steatohepatitis (NASH/MASH).

Scientists at the Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences have synthesized nonstructural protein 14 (NSP14) (coronavirus) inhibitors reported to be useful for the treatment of coronavirus acute respiratory syndrome.

Inflamax Pharmaceuticals (Guangzhou) Co. Ltd. has disclosed proprotein convertase subtilisin/kexin-type 6 (PCSK6; PACE4; PC7A) inhibitors reported to be useful for the treatment of osteoarthritis.